Stella-Jones Announces Third Quarter Results

(TSX:SJ), Sales of $958 million, up 5% from Q3 2024 Operating income of $135 million, up 4% from Q3 2024 EBITDA(1) of $171 million, or 17.8% margin(1), up 6% from Q3 2024 Available liquidity of almost $800 million Normal Course Issuer Bid announced for 2025-2026 Post-quarter acquisition of Brooks, a crossarm manufacturer MONTREAL, Nov. 05, […]

ScottsMiracle-Gro Reports Strong Fiscal 2025 Full-Year Results Driven by Robust Gross Margin Expansion and EPS Growth

(NYSE:SMG), MARYSVILLE, Ohio, Nov. 05, 2025 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG), the leading marketer of branded consumer lawn and garden products in North America, today announced its results for the fourth quarter and full fiscal year ended September 30, 2025. “In fiscal '25, we delivered significant results in the financial metrics

PLAYBOY Announces Winter Issue Featuring Rare Vintage Images of Jane Birkin, 12 New Playmates, Kid Cudi, Sharon Stone and More, on Stands November 11, 2025

(NasdaqGM:PLBY), LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) — Playboy, Inc. (NASDAQ: PLBY) (the “Company” or “Playboy”) unveils its Winter 2025-26 issue, featuring the re-release of rarely seen, semi-nude images of Jane Birkin — the global icon and namesake of the world's most famous handbag — originally published by the magazine in 1970. The pictorial

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

(NasdaqGM:SKYE), SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Monday, November 10, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its third quarter 2025 financial

Plug Power Begins 5 MW Electrolyzer Installation for H2 Hollandia, Set to Become the Largest Green Hydrogen Initiative in the Netherlands

(NASDAQ:PLUG), SLINGERLANDS, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced it has started installation of its 5 MW electrolyzer for the H2 Hollandia project, the first decentralized green hydrogen hub initiative currently under construction in the Netherlands. Developed

Bocana Resources Corp. provides Corporate Update

(TSX-V:BOCA),(Boerse Frankfurt – Freiverkehr:VC1.F),(Boerse Frankfurt – Freiverkehr:VC1), CALGARY, Alberta, Nov. 05, 2025 (GLOBE NEWSWIRE) — Bocana Resources Corp. (TSXV: BOCA) (Frankfurt: VC1) (“Bocana” or the “Company“) is pleased to provide an update to its current activities in Arizona, Colorado, and with our funding/tokenization platform partner Arizore Ltd. In Arizona, the recently drilled samples and portions

Alpha Modus Files Patent-Infringement Lawsuit Against Adroit Worldwide Media (AWM) Over Cashierless and Smart-Shelf Technologies

(NASDAQ:AMOD),(NASDAQ:AMODW), CORNELIUS, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (NASDAQ: AMOD) subsidiary Alpha Modus, Corp. announced that it has filed a federal patent-infringement lawsuit in the U.S. District Court for the Central District of California against Adroit Worldwide Media, Inc. (“AWM”), alleging unauthorized use of Alpha Modus's patented retail-intelligence and cashierless-checkout

NevGold Announces Up to 85% Antimony Recovery From Positive Phase II Metallurgical Testwork at Oxide Gold-Antimony Limo Butte Project in Nevada

(TSX-V:NAU),(OTC US:NAUFF),(Other OTC:NAUFF),(Boerse Frankfurt – Freiverkehr:5E50),(Boerse Frankfurt – Freiverkehr:5E50.F), Vancouver, British Columbia, Nov. 05, 2025 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company“) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce further positive antimony (“Antimony”, “Sb”) metallurgical testwork results at its oxide gold-antimony Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada, one of the

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

(NASDAQ:CNTA), ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026

Scroll to Top